HEMEBIOTECH AS has a total of 17 patent applications. Its first patent ever was published in 1999. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and South Africa. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are VIRALYTICS LTD, CELLIS SP Z O O [LTD ] and ZOLTAN LAB LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | South Africa | 3 | |
#4 | Canada | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Enzymes | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Fogh Jens | 17 |
#2 | Andersson Claes | 7 |
#3 | Gellerfors Paer | 5 |
#4 | Weigelt Cecilia | 5 |
#5 | Gellerfors Par | 5 |
#6 | Irani Meher | 5 |
Publication | Filing date | Title |
---|---|---|
EP1402014A1 | A process for purification of recombinant porphobilinogen deaminase | |
WO02099092A2 | Production of recombinant human lysosomal alpha-mannosidase | |
AU2002317700A1 | Production of recombinant human arylsulfatase a | |
ZA200200195B | Production of rhPBGD useful for new therapeutic methods for treating patients with acute intermittent porphyria (AIPO) and other porphyric diseases. | |
WO0107065A2 | PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES | |
US6537777B1 | Human porphobilinogen deaminase sequences | |
AU2609799A | Method for treating acute intermittent porphyria (AIP) and other porphyric diseases | |
ZA9900616B | New therapeutic method for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases. |